Jyseleca for the treatment of adults with moderate to severe active rheumatoid arthritis - European Commission approved
The European Commission ( EC ) has granted marketing authorization for Jyseleca ( Filgotinib 200 mg and 100 mg tablets ), a once-daily, oral, JAK1 inhibitor for the treatment of adults with moderate to severe active rheumatoid arthritis who have responded inadequately to, or are intolerant to, one or more disease modifying anti-rheumatic drugs ( DMARDs ).
Jyseleca may be used as monotherapy or in combination with Methotrexate ( MTX ).
Rheumatoid arthritis is a chronic, progressive, systemic, inflammatory disease that can lead to significant and irreversible joint destruction, pain and functional impairment.
Almost 3 million people in Europe are living with rheumatoid arthritis, many of whom do not achieve long-term symptom control, which can lead to more frequent symptom flares and disease progression and can significantly impact their quality of life.
The EC’s decision is supported by data from over 3,500 patients treated with Jyseleca across the phase 3 FINCH and phase 2 DARWIN programs.
In the FINCH studies, Jyseleca consistently achieved ACR20/50/70 criteria, with improvements in all individual ACR components compared with placebo or Methotrexate.
A significantly higher proportion of patients treated with Jyseleca 200 mg plus Methotrexate or other conventional synthetic disease-modifying anti-rheumatic drug(s) ( csDMARD ) achieved low disease activity and/or remission ( DAS28-CRP less than or equal to 3.2 and DAS28-CRP less than 2.6 ) at weeks 12 and 24 compared with placebo or Methotrexate.
In patients who had an inadequate response to Methotrexate, treatment with Jyseleca plus Methotrexate achieved statistically significant inhibition of progression of structural joint damage compared to placebo plus Methotrexate, as assessed using the modified Total Sharp Score ( mTSS ) at week 24.
In the DARWIN 3 phase 2, open-label, long-term extension study, durable ACR20/50/70 responses were maintained for up to three years in patients who received Jyseleca 200 mg as monotherapy or with Methotrexate.
Across the FINCH and DARWIN trials, the most common adverse reactions were nausea, upper respiratory tract infection, urinary tract infection and dizziness.
Rates of herpes zoster and pneumonia were uncommon.
The frequency of serious infections in the Jyseleca 200 mg group was 1.0% compared to 0.6% in the placebo group.
In an integrated safety analysis in seven clinical trials the rates of major adverse cardiac events ( MACE ) and venous thromboembolism ( VTE ) with Jyseleca were comparable to placebo.
The rates of serious infections remained stable with long-term exposure. ( Xagena )
Source: Gilead, 2020
SELECT-CHOICE trial: Upadacitinib more effective than Abatacept in patients with moderate to severe active rheumatoid arthritis and prior inadequate response or intolerance to bDMARD
New phase 3 data from the SELECT-CHOICE clinical trial have shown that Upadacitinib ( Rinvoq ), 15 mg, once daily,...
Upadacitinib, a JAK1-selective inhibitor, for adults with moderately to severely active rheumatoid arthritis who fail to adequately respond or are intolerant to Methotrexate
Upadacitinib ( Rinvoq ) was developed as a JAK1-selective inhibitor by exploiting differences in the non-conserved domains outside the active...
Anifrolumab, a human monoclonal antibody to the type I IFN receptor subunit 1, had robust efficacy in a phase 2...
A meta-analysis of phase III, randomised, placebo-controlled trials has assessed the benefits and harms of Pregabalin ( Lyrica ) in...
FDA has approved Keytruda for adult and pediatric patients with classical Hodgkin lymphoma refractory to treatment, or who have relapsed after three or more prior lines of therapy
The FDA ( U.S. Food and Drug Administration ) has approved Keytruda ( Pembrolizumab ), the anti-PD-1 ( programmed death...
European Commission has approved Empliciti for the treatment of multiple myeloma in adult patients who have received at least one prior therapy
The European Commission has approved Empliciti ( Elotuzumab ) for the treatment of multiple myeloma as combination therapy with Revlimid...
Heavily pre-treated patients with relapsed or refractory classical Hodgkin lymphoma: Pembrolizumab, as a monotherapy, shows overall response rates of 73 to 83%, with complete response rates of 27 to 30%
The findings from KEYNOTE-087, the phase 2 study investigating the use of Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, as...
Relapsing-remitting multiple sclerosis: Tysabri in highly active patients with inadequate response to prior therapy
The Committee of Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has...
Moderate to severe systemic lupus erythematosus: Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody, improves symptoms in multiple organ domains including skin and joints
Anifrolumab is an investigational, fully human monoclonal antibody that binds to subunit 1 of the type I IFN receptor, inhibiting...